Home » Topics » BioWorld Science, Endocrine/metabolic

BioWorld Science, Endocrine/metabolic
RSS

Genzyme identifies new GALC inhibitors

April 21, 2020

FAM13A variants lead to changes in adipocyte differentiation regulation and body fat distribution

April 21, 2020

Ascendis reports fixed-dose TransCon PTH data from phase II PaTH Forward trial in hypoparathyroidism

April 20, 2020

PS-PLA1 as new therapeutic target in hyperthyroidism disorders

April 20, 2020

Shanghai Ennova Biopharmaceutical describes new SSAO inhibitors

April 16, 2020

New melanocortin MC4 receptor agonists identified at Palatin Technologies

April 14, 2020

Jnana Therapeutics describes new compounds targeting mutant mammalian proteins

April 9, 2020

Clinical trial application for ACN-00177 approved in the U.K.

April 9, 2020

Selective circadian regulation may yield new therapies

April 8, 2020

FDA clears Polaryx's IND for PLX-200 in juvenile neuronal ceroid lipofuscinosis

April 8, 2020

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for July 17, 2026.
Dual FAAH/MAGL inhibition targets Alzheimer’s disease hyperexcitability
BioWorld Science
Reduced endocannabinoid signaling has been linked to neuronal hyperexcitability in Alzheimer’s disease (AD), suggesting that dual inhibition of fatty acid amide...
ALN-5288 lowers tau levels in preclinical models
BioWorld Science
Pathological tau accumulation is a key driver of neurodegeneration in Alzheimer’s disease (AD) and other tauopathies such as progressive supranuclear palsy....
Capital remains selective in ‘barbell’ biotech market
BioWorld
Signs of recovery are emerging in the biotechnology investment sector, although investors across Asia say that capital is flowing selectively to companies that...
PSB-229 reduces plaque burden in Alzheimer’s models
BioWorld Science
Pyroglutamate-modified amyloid-β (pE3-Aβ) is a highly pathogenic Aβ species that accumulates within amyloid plaques and contributes to aggregation,...